Standard of Care in First-Line Therapy of DLBCL-Reference-Cited by-同舟云学术

Standard of Care in First-Line Therapy of DLBCL

Published:2018-12-28 Issue: Volume: Page:145-155
ISSN:2194-0770
Container-title:Künstliche Photosynthese
language:
Short-container-title:

Author:

Nowakowski Greg,Frontzek Fabian,Schmitz Norbert

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-030-00362-3_5

Reference75 articles.

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC Publications; 2017.

2. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15(7):757–66.

3. Glass B, Dohm AJ, Truemper LH, Pfreundschuh M, Bleckmann A, Wulf GG, et al. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial. Ann Oncol. 2017;28(12):3058–64.

4. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

5. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484–93.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper;Hematological Oncology;2022-06-07